Project description
Immune cell tracking during immunotherapy
Cancer immunotherapy can help the immune system recognise and attack cancer cells. Treatments include monoclonal antibodies, cytokines, adoptive immune cell transfer or other immune-modulating approaches. Despite their promise, the mechanisms behind these therapies remain poorly understood, particularly how immune cells relocate and interact post-treatment. With the support of the Marie Skłodowska-Curie Actions programme, the T-RAFIC project aims to increase knowledge of immune cell trafficking during therapy, especially during immunotherapy combinations. The consortium will employ technological advancements to enable unprecedented tracking of immune cells and ultimately contribute to improve treatment efficacy in this emerging field in oncology and beyond.
Objective
Cancer immunotherapies have been established in a growing number of clinical indications and the pace of development is massively accelerating. Currently over 6.000 clinical trials are investigating immune-related treatments in oncology especially in combinations. It includes both adoptive cellular therapies and immune modulating treatments like immune check point blockade. In contrast, the understanding of how such therapies mediate their mode of action is still mostly poorly understood. In particular, the role of distribution and relocation of immune cells after therapeutic interventions remains unknown. This is surprising, as immune cell interactions are a hallmark of therapeutic immune responses. T-RAFIC will enhance understanding of immune cell trafficking under therapeutic influence. It will open new paths and avenues to treatments, boost their efficacy and help prioritizing the plethora of immune therapeutic combinations. In the past, detailed analysis of cellular distributions was facing technical barriers. Advances in technologies, now permit tracking and visualization of cells in vitro and in vivo at an unprecedented resolution, allowing for the first time studies on immune cells under therapeutic influence. This emerging field of research has enormous potential and key importance for next generation of researchers in oncology and beyond. However, experts in this field are missing and this threats European research, development and medicine. Therefore, T-RAFIC joins forces of 13 academic and three industrial partners from nine European countries to conduct an innovative and interdisciplinary approach combining cell imaging with bioinformatics, cell engineering and clinician expertise. The network bundles recognised expertise in cancer immunotherapies, empowering European research and innovation and ensuring a sustainable cooperation in science and training.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesclinical medicineoncology
- medical and health sciencesbasic medicineimmunologyimmunotherapy
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Programme(s)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Funding Scheme
HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral NetworksCoordinator
80539 MUNCHEN
Germany
See on map
Participants (10)
2800 Kongens Lyngby
See on map
1081 HV Amsterdam
See on map
3400 Hillerod
See on map
94805 Villejuif
See on map
75654 Paris
See on map
6020 Innsbruck
See on map
51429 Bergisch Gladbach
See on map
20090 Pieve Emanuele
See on map
0450 Oslo
See on map
81675 MUENCHEN
See on map
Partners (14)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
80333 Muenchen
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
6020 Innsbruck
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
CM1 1SQ Chelmsford
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
6900 Lugano
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
75006 Paris
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
1165 Kobenhavn
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
0313 Oslo
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
35042 Rennes
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
1081 HV Amsterdam
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
8952 Schlieren
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
6500 Bellinzona
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
91190 Gif-Sur-Yvette
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
81377 Munchen
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
NG1 1GF Nottingham
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.